The analgesic efficacy of fentanyl: Relationship to tolerance and μ-opioid receptor regulation

Pharmacology Biochemistry and Behavior

Volumn 91, Issue 1, 2008, Pages 115-120

  Sirohi, Sunil ^a   Dighe, Shveta V ^a   Walker, Ellen A ^b   Yoburn, Byron C ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

Opioid receptor; Analgesia; Efficacy; Fentanyl; Opioid agonist; Receptor downregulation; Tolerance

Indexed keywords

CLOCINNAMOX; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ETORPHINE; FENTANYL; MORPHINE; MU OPIATE RECEPTOR; OXYCODONE; PLACEBO; SODIUM CHLORIDE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TOLERANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR UPREGULATION;

ANALGESICS, OPIOID; ANIMALS; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG TOLERANCE; FENTANYL; MALE; MICE; MORPHINE; PAIN MEASUREMENT; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, MU; SPINAL CORD;

MUS;

EID: 50349083730     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.06.019     Document Type: Article

References (45)

1. Adams J.U., Paronis C.A., and Holtzman S.G. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine. J Pharmacol Exp Ther 255 (1990) 1027-1032
2. Barrett A.C., Smith E.S., and Picker M.J. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox. J Pharmacol Exp Ther 305 (2003) 1061-1070
3. Black J.W., Leff P., Shankley N.P., and Wood J. An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol 84 (1985) 561-571
4. Black J.W., and Leff P. Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220 (1983) 141-162
5. Bohn L.M., Dykstra L.A., Lefkowitz R.J., Caron M.G., and Barak L.S. Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol Pharmacol 66 (2004) 106-112
6. Bradford M.M. A refined and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
7. Burke T.F., Woods J.H., Lewis J.W., and Medzihradsky F. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice. J Pharmacol Exp Ther 271 (1994) 715-721
8. Chan K., Brodsky M., Davis T., Franklin S., Inturrisi C.E., and Yoburn B.C. The effect of the irreversible mu-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA. Eur J Pharmacol 287 (1995) 135-143
9. Clark M.J., Furman C.A., Gilson T.D., and Traynor J.R. Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation. J Pharmacol Exp Ther 317 (2006) 858-864
10. Duttaroy A., and Yoburn B.C. The effect of intrinsic efficacy on opioid tolerance. Anesthesiol 82 (1995) 1226-1236
11. Duttaroy A., Kirtman R., Farrell F., Phillips M., Philippe J., Monderson T., et al. The effect of cumulative dosing on the analgesic potency of morphine in mice. Pharmacol Biochem Behav 58 (1997) 67-71
12. Ferguson S.S., Downey W.E., Colapietro A.M., Barak L.S., Ménard L., and Caron M.G. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 271 (1996) 363-366
13. Ferguson S.S., Zhang J., Barak L.S., and Caron M.G. Role of beta-arrestins in the intracellular trafficking of G-protein-coupled receptors. Adv Pharmacol 42 (1998) 420-424
14. Finney D.J. Probit analysis. 3rd ed. (1973), Cambridge University Press, London
15. Furchgott R.F., and Bursztyn P. Comparison of dissociation constants and of relative efficacies of selected agonists acting on parasympathetic receptors. Ann NY Acad Sci 144 (1967) 882-898
16. Furchgott R.F. The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. In: Harper N.J., and Simmonds A.B. (Eds). Advances in drug research vol. 3 (1966), Academic Press 21-55
17. Galandrin S., and Bouvier M. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70 (2006) 1575-1584
18. Haberstock-Debic H., Kim K.A., Yu Y.J., and von Zastrow M. Morphine promotes rapid, arrestin-dependent endocytosis of μ-opioid receptors in striatal neurons. J Neurosci 25 (2005) 7847-7857
19. Keith D.E., Anton B., Murray S.R., Zaki P.A., Chu P.C., Lissin D.V., et al. mu-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 53 (1998) 377-384
20. Kenakin T. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 28 (2007) 407-415
21. Kenakin T. Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42 (2002) 349-379
22. Kieffer B.L. Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20 (1999) 19-26
23. Koch T., Widera A., Bartzsch K., Schulz S., Brandenburg L.O., Wundrack N., et al. Receptor endocytosis counteracts the development of opioid tolerance. Mol Pharmacol 67 (2005) 280-287
24. Leff P., Prentice D.J., Giles H., Martin G.R., and Wood J. Estimation of agonist affinity and efficacy by direct, operational model-fitting. J Pharmacol Methods 23 (1990) 225-237
25. Mailman R.B. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 28 (2007) 390-396
26. Martini L., and Whistler J.L. The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol 17 (2007) 556-564
27. Motulsky H.J., and Christopoulos A. Fitting models to biological data using linear and nonlinear regression. A practical guide to curve fitting (2004), Oxford University Press, New York
28. Paronis C.A., and Holtzman S.G. Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats. J Pharmacol Exp Ther 262 (1992) 1-9
29. Patel M.B., Patel C.N., Rajashekara V., and Yoburn B.C. Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo. Mol Pharmacol 62 (2002) 1464-1470
30. Patel C.N., Rajashekara V., Patel K., Purohit V., and Yoburn B.C. Chronic opioid antagonist treatment selectively regulates trafficking and signaling proteins in mouse spinal cord. Synapse 50 (2003) 67-76
31. Pawar M., Kumar P., Sunkaraneni S., Sirohi S., Walker E.A., and Yoburn B.C. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of μ-opioid receptors and dynamin-2. Eur J Pharmacol 563 (2007) 92-101
32. Peckham E.M., and Traynor J.R. Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther 316 (2006) 1195-1201
33. Rodríguez-Muñoz M., de la Torre-Madrid E., Sánchez-Blázquez P., and Garzón J. Morphine induces endocytosis of neuronal mu-opioid receptors through the sustained transfer of Galpha subunits to RGSZ2 proteins. Mol Pain 3 (2007) 19
34. Selley D.E., Liu Q., and Childers S.R. Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamu. J Pharmacol Exp Ther 285 (1998) 496-505
35. Selley D.E., Sim L.J., Xiao R., Liu Q., and Childers S.R. Mu-opioid receptor-stimulated guanosine-5′-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol 51 (1997) 87-96
36. Shah S., Duttaroy A., Davis T., and Yoburn B.C. Spinal and supraspinal effects of pertussis toxin on opioid analgesia. Pharmacol Biochem Behav 49 (1994) 773-776
37. Stafford K., Gomes A.B., Shen J., and Yoburn B.C. Mu-opioid receptor downregulation contributes to opioid tolerance in vivo. Pharmacol Biochem Behav 69 (2001) 233-237
38. Waldhoer M., Bartlett S.E., and Whistler J.L. Opioid receptors. Annu Rev Biochem 73 (2004) 953-990
39. Walker E.A., and Young A.M. Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats. Psychopharmacology (Berl) 154 (2001) 131-142
40. Whistler J.L., and von Zastrow M. Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci USA 95 (1998) 9914-9919
41. Whistler J.L., Chuang H.H., Chu P., Jan L.Y., and von Zastrow M. Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23 (1999) 737-746
42. Yoburn B.C., Billings B., and Duttaroy A. Opioid receptor regulation in mice. J Pharmacol Exp Ther 265 (1993) 314-320
43. Zernig G., Issaevitch T., Broadbear J.H., Burke T.F., Lewis J.W., Brine G.A., et al. Receptor reserve and affinity of mu opioid agonists in mouse antinociception: correlation with receptor binding. Life Sci 57 (1995) 2113-2125
44. Zernig G., Issaevitch T., and Woods J.H. Calculation of agonist efficacy, apparent affinity, and receptor population changes after administration of insurmountable antagonists: comparison of different analytical approaches. J Pharmacol Toxicol Methods 35 (1996) 223-237
45. Zheng H., Loh H.H., and Law P.Y. Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) translocate to nucleus in contrast to G protein-dependent ERK activation. Mol Pharmacol 73 (2008) 178-190